News | Cardiac Diagnostics | October 06, 2020

Rapid Heart Function Analysis by Avalon-H90 Device May Identify Myocarditis In COVID-19 Patients

The Mesuron Inc. Avalon-H90 uses magnetometers to detect myocarditis in patients without any physical contact. It uses ventricular repolarization dynamics analysis software to look for abnormalities. The vendor said it is more specific than using ECG. It detects the multidimensional dynamics of the electrical activity caused by differences in functions of electrical action potential of normal heart tissues and abnormal ones with hypoxia.

The Mesuron Inc. Avalon-H90 uses magnetometers to detect myocarditis in patients without any physical contact. It uses ventricular repolarization dynamics analysis software to look for abnormalities. The vendor said it is more specific than using ECG. It detects the multidimensional dynamics of the electrical activity caused by differences in functions of electrical action potential of normal heart tissues and abnormal ones with hypoxia. 


October 6, 2020 — A new technology being developed by U.S.-based Mesuron Inc. using a superconducting quantum interference device (SQUID)-based magnetometers is being used for heart screenings and may be able to quickly detect myocarditis in COVID-19 patients without any physical contact. The medical device called Avalon-H90.

COVID-19 causes myocarditis in many of those infected. So, there is a need for fast, noninvasive and reliable heart screening for all patients who were affected by COVID-19 and potentially developed myocarditis.

According to the article published by Ohio State University Sept. 11, 2020 in medical journal JAMA, 26 competitive athletes who had COVID-19 had symptoms of myocarditis.[1] Myocarditis affects the heart muscle and can cause heart failure or sudden death. Steven Erickson, M.D., a sports medicine specialist at Banner — University Medical Center in Phoenix, Ariz., told USA Today that athletes should be symptom-free for two weeks before getting back into the game.

Although widely used as a screening tool, the sensitivity of electrocardiogram (ECG) for myocarditis is only less than 50 percent and is very non-specific. The most common ECG findings are non-specific T-wave changes.

The Mesuron team believes its technology is most sensitive to detect any T-wave changes. It is fast, non-invasive, no injection, no radiation, no contact, high sensitivity at rest detection of ventricular myocardial repolarization abnormalities, that reflects several myocardial problems, including ischemia.

Mesuron Inc. has developed Ventricular Repolarization Dynamics Analysis (VRDA) on the Avalon-H90 that detects the multidimensional dynamics of the electrical activity caused by differences in functions of electrical action potential (EAP) of normal heart tissues and abnormal ones with hypoxia. The vendor says is also robust enough to detect abnormalities without hypoxia due to changes in muscle chemistry related to insufficient blood supply or other myocardial abnormalities.

Avalon-H90 takes approximately 5 minutes to deliver test results that can separate high and low risk cardiac patients and help the physician make early decisions.

Avalon-H90 is a fully developed prototype. It is designed for use in hospitals' emergency departments and outpatient clinics. The company is looking for partnerships to conduct a medical trial for detecting myocardial abnormalities in acute chest pain (ACP) patients. One trial has already been arranged with Mayo Clinic. 

For more information: www.mesuron.com

Read more about this technology being developed by another start up company:

Key Technology and News at AHA 2018

VIDEO: Editor's Choice of the Most Innovative New Cardiac Technology at AHA 2018
 

    

Reference:

1. Saurabh Rajpal, Matthew S. Tong, James Borchers, et al. Cardiovascular Magnetic Resonance Findings in Competitive Athletes Recovering From COVID-19 Infection. JAMA Cardiol. Published online September 11, 2020. doi:10.1001/jamacardio.2020.4916.

 
 

Related Content

News | Cardiac Diagnostics

October 4, 2021 – Nanowear, a hospital-at-home and remote diagnostic platform that used proprietary wearable cloth ...

Home October 04, 2021
Home
News | Cardiac Diagnostics

September 28, 2021 — Biotricity Inc., a medical diagnostic and consumer healthcare technology company, has developed a ...

Home September 28, 2021
Home
News | Cardiac Diagnostics

July 29, 2021 — A recent clinical study from Overlake Medical Center utilizing the Bardy Diagnostics Carnation ...

Home July 29, 2021
Home
News | Cardiac Diagnostics

July 1, 2021 — The U.S. Food and Drug Administration (FDA) has cleared the Angel Medical Systems Inc. second-generation ...

Home July 01, 2021
Home
News | Cardiac Diagnostics

March 8, 2021 — In a new study from Shiley Eye Institute at UC San Diego Health, researchers have identified a potential ...

Home March 08, 2021
Home
News | Cardiac Diagnostics

March 3, 2021 — AliveCor recently announced a new collaboration with AstraZeneca to research new disease management ...

Home March 03, 2021
Home
News | Cardiac Diagnostics

February 2, 2021 — A new study has found in the U.S. shows higher economic prosperity was associated with a small ...

Home February 02, 2021
Home
News | Cardiac Diagnostics

January 6, 2021 — Smoking traditional cigarettes in addition to using e-cigarettes results in harmful health effects ...

Home January 06, 2021
Home
News | Cardiac Diagnostics

May 11, 2020 — The American Society for Preventive Cardiology (ASPC) is collaborating with Intervent International to ...

Home May 11, 2020
Home
News | Cardiac Diagnostics

March 5, 2020 — More than 300 patients have joined the Amyloidosis Patient Registry and it is now available to the ...

Home March 05, 2020
Home
Subscribe Now